Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.
Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.
The objective of the present study is to evaluate the capability of the probiotic strain
 Lactobacillus coryniformis K8 CECT5711 (Lc K8) to enhance the immune response to influenza
 vaccine in elderly and the effect on respiratory symptoms related to respiratory infections.

 A randomized, double-blind, placebo-controlled trial was conducted between November of 2015
 and April of 2016. A total of 98 residents of nursing homes aged more than 65 years were
 randomly assigned to receive Lc K8 or placebo for two weeks previous to influenza
 vaccination.

 Primary outcome was the percentage of seroconversion. Secondary outcome were the incidence of
 influenza-like illness and respiratory symptoms associated to respiratory infections during
 the follow-up period of 5 months. Serum cytokines and immunoglobulins levels were also
 evaluated.
The objective of the present study is to evaluate the capability of Lc K8 to enhance the
 immune response to influenza vaccine in elderly and the effect on respiratory symptoms
 related to respiratory infections.

 A randomized, double-blinded, placebo controlled, multicenter trial was performed. The study
 was started on October 2015 and ended on April 2016. The recruitment of volunteers was
 carried out in five nursing home of Granada (Spain) at the beginning of the vaccination
 program.

 Volunteers were randomly assigned to one of two groups. Those in the placebo group daily
 consumed a capsule containing 300 mg of maltodextrin. Those in the probiotic group daily
 consumed a capsule containing 3x10(9) colon-forming units of the strain Lc K8 in a matrix of
 maltodextrin.

 From two weeks previous to the beginning of the intervention the consumption of any probiotic
 supplement was restricted until the end of the study. During two weeks before flu vaccination
 volunteers daily received a capsule of probiotic or placebo. Day 15 of the study all
 volunteers received intramuscular vaccination against flu (inactivated trivalent influenza:
 A/California/7/22009[H1N1]pdm09, A/HongKong/4801/2014[H3N2], B/Brisbane/60/2002) for the
 vaccine campaign of 2015/2016 (Sanofi Pasteur Europe, Lyon, France). All volunteers were
 vaccinated during the same week (second week of November 2015). After vaccination volunteer
 were followed-up until 31 of April 2016.
Inclusion Criteria:

 -  Residents in nursing home aged more than 65 years

 Exclusion Criteria:

 -  Frequent gastrointestinal diseases, antibiotic treatment during the intervention,
 allergy to any groups of antibiotics, egg proteins or adjuvants and excipients of the
 flu vaccine